Premiere Date: July 20, 2019
Expiration Date: January 20, 2021
This activity offers CE credits for:
1. Physicians (CME)
All other clinicians either will receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
The goal of this activity is to provide a comprehensive understanding for the identification, assessment, and clinical management of tardive dyskinesia.
At the end of this CE activity, participants should be able to:
• Discuss what is known about the pathology of tardive dyskinesia as well as the risk factors for the disorder
• Assess a patient with movement disorder and make a diagnosis
• Identify FDA-approved pharmacotherapies for tardive dyskinesia
This continuing medical education activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.
CME Credit (Physicians): This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC, and Psychiatric Times. CME Outfitters, LLC, is accredited by the ACCME to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners and Physician Assistants: AANPCP and AAPA accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer-review process.
The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Melissa Palmer, PharmD, has no disclosures to report.
Austin R. Campbell, PharmD, reports that he is on the Speakers Bureau of Sunovion Pharmaceuticals.
Amber Finegan, PharmD, has no disclosures to report.
Leigh Anne Nelson, PharmD, reports that she has received research support from Neurocrine Biosciences and Teva Neuroscience; her husband is a shareholder in Neurocrine Biosciences.
Vivek Datta, MD (peer/content reviewer), has no disclosures to report.
Applicable Psychiatric Times staff and CME Outfitters staff have no disclosures to report.
UNLABELED USE DISCLOSURE
Faculty of this CME/CE activity may include discussion of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA-labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
For content-related questions, email us at [email protected]; for questions concerning CME credit call us at 877.CME.PROS (877.263.7767)
Dr Palmer is a Board Certified Pharmacotherapy Specialist and Psychiatric Pharmacist; she is also Clinical Assistant Professor of Pharmacy Practice and Administration, University of Missouri-Kansas City School of Pharmacy, Kansas City, MO. Dr Campbell is a Board Certified Psychiatric Pharmacist and Clinical Pharmacy Specialist in Psychiatry, University of Missouri Health Care, Columbia, MO. Dr Finegan is a PGY2 Psychiatric Pharmacy Practice Resident, Center for Behavioral Medicine, Kansas City, MO. Dr Nelson is a Board Certified Psychiatric Pharmacist and Professor of Pharmacy Practice and Administration, University of Missouri-Kansas City School of Pharmacy, Kansas City, MO.
1. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486-487.
2. Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handbk Clin Neurol. 2011;100:601-616.
3. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(Suppl 2):1-56.
4. Zheng W, Xiang Y-Q, Ng CH, et al. Extract of ginkgo biloba for tardive dyskinesia: meta-analysis of randomized controlled trials. Pharmacopsychiatry. 2016;49:107-111.
5. Crosby NJ, Deana KH, Clarke CE. Amantadine for dyskinesia in Parkinson disease. Cochrane Database Syst Rev. 2003; CD003467.
6. Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33:271-275.
7. Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17:88-91.
8. Bhidayasiri R, Fahn S, Weiner WJ. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81:463-469.
9. Kaur N, Kumar P, Jamwal S, et al. Tetrabenazine: spotlight on drug review. Ann Neurosci. 2016;23:176-185.
10. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia (ARM-TD). Neurology. 2017;88:2003-2010.
11. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patient with tardive dyskinesia (AIM-TD). Lancet Psychiatry. 2017;4:595-604.
12. Citrome L. Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication. Int J Clin Pract. July 2017; Epub.
13. Solmi M, Pigato G, Kane JM, et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systemic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215-1238.
14. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476-484.
15. Cornett EM, Novitch M, Kaye AD, et al. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017;17:162-174.
16. Correll CU, Kane JM, Citrome LL. Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J Clin Psychiatry. 2017;78:1136-1147.
17. Carbon M, Hsie CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78:e264-e278.
18. Jankelowitz SK. Treatment of neuroleptic-induced tardive dyskinesia. Neuropsych Dis Treat. 2013;9:1371-1380.
19. Macaluso M, Flynn A, Preskorn SH. Tardive dyskinesia: a historical perspective. J Psych Pract. 2017;23:121-129.